RecruitingNot ApplicableNCT04861415

SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer

A Randomized Feasibility Trial of Stereotactic Body Radiotherapy Versus Conventional Fractionation With High Dose-rate (HDR) Brachytherapy Boost for Prostate Cancer

Sponsor

Dr. Gerard Morton

Enrollment

55 participants

Start Date

Dec 23, 2020

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two types of radiation treatment for prostate cancer: a shorter, high-dose course (SBRT) versus a more traditional longer course combined with internal radiation (HDR brachytherapy boost), to see which is more effective and has fewer side effects. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with prostate cancer confirmed by biopsy - You are in good to fair general health (ECOG 0–2) - You have not previously had pelvic radiation, brachytherapy, cryotherapy, HIFU, TURP, or prostate removal surgery **You may NOT be eligible if...** - Your cancer has spread to lymph nodes or other parts of the body - You have had previous prostate surgery or radiation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.